TY - JOUR T1 - Healthcare-associated COVID-19 in England: a national data linkage study JF - medRxiv DO - 10.1101/2021.02.16.21251625 SP - 2021.02.16.21251625 AU - Alex Bhattacharya AU - Simon M Collin AU - James Stimson AU - Simon Thelwall AU - Olisaeloka Nsonwu AU - Sarah Gerver AU - Julie Robotham AU - Mark Wilcox AU - Susan Hopkins AU - Russell Hope Y1 - 2021/01/01 UR - http://medrxiv.org/content/early/2021/02/19/2021.02.16.21251625.abstract N2 - Objectives Nosocomial transmission was an important aspect of SARS-CoV-1 and MERS-CoV outbreaks. Healthcare-associated SARS-CoV-2 infection has been reported in single and multi-site hospital-based studies in England, but not nationally.Methods Admission records for all hospitals in England were linked to SARS-CoV-2 national test data for the period 01/03/2020 to 31/08/2020. Case definitions were: community-onset community-acquired (CO.CA), first positive test (FPT) <14 days pre-admission, up to day 2 of admission; hospital-onset indeterminate healthcare-associated (HO.iHA), FPT on day 3-7; hospital-onset probable healthcare-associated (HO.pHA), FPT on day 8-14; hospital-onset definite healthcare-associated (HO.HA), FPT from day 15 of admission until discharge; community-onset possible healthcare-associated (CO.pHA), FPT ≤14 days post-discharge.Results One-third (34.4%, 100,859/293,204) of all laboratory-confirmed COVID-19 cases were linked to a hospital record. HO.pHA and HO.HA cases represented 5.3% (15,564/293,204) of all laboratory-confirmed cases and 15.4% (15,564/100,859) of laboratory-confirmed cases among hospital patients. CO.CA and CO.pHA cases represented 86.5% (253,582/293,204) and 5.1% (14,913/293,204) of all laboratory-confirmed cases, respectively.Conclusions Up to 1 in 6 SARS-CoV-2 infections among hospitalised patients with COVID-19 in England during the first 6 months of the pandemic could be attributed to nosocomial transmission, but these represent less than 1% of the estimated 3 million COVID-19 cases in this period.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors. SH, JR and RH are partly funded by the National Institute for Health Research (NIHR) Health Protection Research Unit (HPRU) in Healthcare-Associated Infections and Antimicrobial Resistance in a partnership between Public Health England (PHE) and the University of Oxford [NIHR200915]. AB, SH, SC and RH work on a data project within PHE that is funded by an NIHR AMR award [NIHR200658].Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The PHE Research Support and Governance Office exempted this study from full ethical review. The research was classified as surveillance undertaken as part of PHEs legal responsibility to monitor COVID-19 and was found to be fully compliant with all current regulatory requirements.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesRequests for aggregate data not otherwise shown in the manuscript and supplementary files can be sent to the corresponding author. ER -